To fully comprehend the mechanism of therapeutic action and appreciate the enormous potential of IL-4R alpha targeting medicines, it is essential to have a basic understanding of the molecular ...

Patients with moderate to severe asthma saw increases in FEV1 within 24 hours after taking a loading dose of rademikibart, ...

ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases. ATI-052 targets thymic stromal ...

Please provide your email address to receive an email when new articles are posted on . By inhibiting IL-4R alpha in aspirin-exacerbated respiratory disease, dupilumab improved respiratory ...

Aclaris Therapeutics Inc. has gained IND clearance from the FDA for ATI-052, a bispecific anti-thymic stromal lymphopoietin (TSLP)/interleukin-4 receptor (IL-4R) monoclonal antibody being developed to ...

Researchers at Jiangsu Hengrui Medicine Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising ...

Pre-treatment immune biomarkers of pembrolizumab efficacy in patients with glioblastoma treated with standard of care. Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven ...